- Press releases
- Events & Presentations
- Corporate Governance
- Shareholder & Stock Info
- Analyst Coverage
- Financial Reports
- Financial calendar
- Secured Rights issue 2018
- Secured Rights issue 2017
Board of directors
According to the articles of association Immunicum AB (publ)’s (the “Company”) board of directors shall consist of at least three (3) and at most eight (8) board members without deputies. The Company’s board of directors currently consists of six (6) board members, including the chairman of the board of directors. All board members have been appointed until the end of next annual general meeting. Information regarding the Company’s board members, including year of birth, education and experiences, year of election to the board of directors, ongoing engagements, and past engagements during the past five (5) years and shareholding in the Company (including indirect holdings and related persons’ holdings), can be found below.
Interim Chairman since 2021
Shares: 15,000 (through related) MBA in Finance and Management from Columbia Business School Born: 1974
Christine Lind is an American citizen, born in 1974. Christine Lind holds a bachelor’s degree in finance and information system from New York University, Stern School of Business, and an MBA-degree in finance and management from Columbia Business School. Christine Lind has extensive experience from management roles in the global biotech industry (e.g. Vice President Business Development at LifeCell Corporation and Executive Vice President Business Development and subsequently CEO of Medivir AB) and as a strategic and financial advisor to biotech and pharmaceutical companies (at Merrill Lynch & Co). Christine Lind is currently a board member of Xspray Pharma and CEO and chairman of the board of directors of Lind Growth Strategy AB.
Ongoing engagements: Board member of Xspray Pharma and CEO and chairman of the board of directors of Lind Growth Strategy AB
Independency: Christine Lind is independent in relation to the company, its senior executives and major shareholders.
ANDREA VAN ELSAS
BOARD MEMBER SINCE 2021
Ph.D. in Immunology and Oncology and an M.S. in Molecular and Cell Biology Born: 1966
Experience: He has previously served as Chief Scientific Officer at Aduro Biotech, following the acquisition of BioNovion, a company he co-founded in 2011, and held various positions at Organon (acquired by Schering-Plough and later by Merck) in The Netherlands and Cambridge, Massachusetts, US. While working for Organon and Schering-Plough, he directed the immuno-oncology portfolio and led the anti-PD1 program that later became known as pembrolizumab. As a postdoctoral researcher, he worked in the lab of 2018 Nobel Laureate Jim Allison at the University of California, Berkeley and is a co-inventor on the original anti-CTLA-4 patents that formed the basis for the development of ipilimumab, the first checkpoint inhibitor approved in 2011 by the FDA for the treatment of melanoma.
Ongoing assignments: Venture partner with Third Rock Ventures and serves on the Scientific Advisory boards of Lava Therapeutics (chair) and InteRNA Technologies.
Independency: Andrea van Elsas is independent in relation to the company, its senior executives, and major shareholders.
Board member since 2016
Shares: 4,000 M.D., Ph.D., Karolinska Institute, Stockholm Born: 1958
Experience: Charlotte Edenius has more than 20 years of experience from senior executives in pharmaceutical- and biotech companies, including experience from development of pharmaceuticals, regulatory issues and marketing. Charlotte has previously worked as Executive Vice President (R&D) at Medivir AB, Senior Vice President (R&D) at Orexo AB and as Vice President Research at Biolipox AB and various positions within clinical research and development at AstraZeneca.
Ongoing engagements: Chairman of the board of directors and CEO of Allmora Life Science AB. Board member of Kancera AB, and Gesynta Pharma AB.
Past engagements during the last five (5) years: Board member of Karolinska Institutet Innovations AB, Karolinska Development AB, SynAct Pharma AB and Qlucore AB.
Independency: Charlotte Edenius is independent in relation to the company, its senior executives and major shareholders.
BOARD MEMBER SINCE 2021
Shares: 1.323,073 Master's degree in Business Economics, master's degree cum laude in Aerospace Engineering Born: 1976
Experience: CEO and co-founder of SkylineDx, The Netherlands, developing diagnostic tests in oncology. He is also owner and managing director of Exponential BV in which capacity he acts as consultant to Van Herk Investments. Previously he has held various positions in investment banking and asset management including at Kempen & Co and Robeco.
Ongoing assignments: Board member of BioInvent, Ceradis, Medis Medical Imaging, Sensara and Vitalnext as well as advisory board member of BioGeneration Ventures II, Thuja Capital Fund I and Gilde Healthcare Funds II and III.
Independency: Dharminder Chahal is independent in relation to the company and its senior executives, and dependent in relation to the major shareholders.
Board member since 2020
Doctorate in cell and molecular biology in medical science at Lund University Born: 1962
Helén Tuvesson is a Swedish citizen, born in 1962 and holds a doctor’s degree in cellular and molecular biology in medical science at Lund University. She has more than 25 years of experience from the pharmaceutical industry in various positions within Pharmacia and Active Biotech, including as Chief Scientific Officer at Active Biotech for 6 years. In this role she was responsible for the operational research activities and the company’s project portfolio in late stage clinical development in neurodegenerative diseases and cancer indications. Since 2017, Helén is the CEO of Active Biotech AB.
Ongoing engagement: CEO, Active Biotech AB
Independency: Helén Tuvesson is independent in relation to the company, its senior executives and major shareholders.
Board member since 2016
MD, University of Copenhagen and trained in Internal Medicine. Born: 1948
Experience: Steven Glazer is an experienced executive within health and biotech. He has extensive and broad experience from the therapeutic field, including hematology, oncology, hemophilia, HIV, diabetes, allergies and cardiovascular diseases from pharmaceutical and biotech companies in Europe and the USA. He has qualifications from successful planning and implementation of development strategies, regulatory strategies and business strategies, projects and study plans. Steven has been working as Chief Medical Officer at Hansa Medical,Senior Vice President Development at BioInvent, Vice President Development at Zealand Pharma and Medical Director at Novo Nordisk. Steven currently functions as a research and development consultant for various companies.
Ongoing engagements: Owner at Glazer Consulting ApS, Partner at Ventac Partners
Independency: Steven Glazer is independent in relation to the company, its senior executives and major shareholders.
Board member since 2020
MSc from Stockholm School of Economics and Business Administration Born: 1952
Sven Andreasson is a Swedish citizen, born in 1952 and resides in Washington DC, US. Sven holds a degree in business administration from Stockholm School of Economics and MBA-educations from IMEDE Lausanne, INSEAD Fontainebleau and Ashridge London. Sven has a wide experience from both biotech and pharmaceutical companies. He was CEO of Active Biotech in Lund 1999-2008, CEO of Beta- Cell in Belgium 2008-2012 and CEO of Isconova in Uppsala 2012-2013 where he initiated and completed a sale of the company in 2013 to the American company Novavax. Sven is currently working as Senior Vice President of Novavax with responsibility for business development. Sven has also held several senior management positions within Pharmacia in Sweden, Germany, Belgium and France. Previous experience from board assignments includes e.g. TiGenix (Belgium), Immunicum and Cantargia. Current board assignments consist of board member of Cellastra Inc (US) and Erytech SA (France) where he was chairman 2008-2013 and now a board member.
Independency: Sven Andreasson is independent in relation to the company, its senior executives and major shareholders.